AGLE - アエグリア・バイオセラピュ―ティクス (Aeglea BioTherapeutics Inc.)

AGLEのニュース

   Why Aeglea BioTherapeutics Stock Is Way Down Today  2021/12/06 18:01:47 The Motley Fool
MIxed phase 3 clinical trial results are making investors nervous.
   Aeglea BioTherapeutics Announces Achievement of Primary Endpoint in Phase 3 Study of Pegzilarginase in Patients with Arginase 1 Deficiency  2021/12/06 11:30:00 PR Newswire
AUSTIN, Texas, Dec. 6, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that the pivotal Phase 3 study,
   -$0.29 EPS Expected for Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) This Quarter  2021/12/05 04:16:41 Transcript Daily
Brokerages expect Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) to post ($0.29) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Aeglea BioTherapeutics earnings, with the highest EPS estimate coming in at ($0.20) and the lowest estimate coming in at ($0.34). Aeglea BioTherapeutics reported earnings per share of []
   Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Shares Bought by Renaissance Technologies LLC  2021/11/26 09:36:42 Transcript Daily
Renaissance Technologies LLC grew its position in shares of Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) by 383.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 50,787 shares of the biotechnology companys stock after purchasing an additional 40,287 shares during the period. Renaissance Technologies LLC owned []
   Brokerages Expect Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Will Post Quarterly Sales of $3.07 Million  2021/11/22 23:32:41 Dakota Financial News
Analysts expect that Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) will announce sales of $3.07 million for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Aeglea BioTherapeutics earnings, with estimates ranging from $1.40 million to $6.41 million. The company is scheduled to issue its next earnings results on Thursday, March 17th. On []
   Aeglea BioTherapeutics (NASDAQ:AGLE) Earns Outperform Rating from Lifesci Capital  2021/11/06 12:58:42 Transcript Daily
Lifesci Capital reaffirmed their outperform rating on shares of Aeglea BioTherapeutics (NASDAQ:AGLE) in a report issued on Friday morning, Zacks.com reports. Other equities analysts have also issued reports about the company. Zacks Investment Research lowered Aeglea BioTherapeutics from a buy rating to a hold rating in a report on Thursday, August 12th. Evercore ISI initiated []
   Point72 Asset Management L.P. Trims Stock Position in Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE)  2021/11/04 12:08:42 Transcript Daily
Point72 Asset Management L.P. cut its stake in shares of Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) by 68.7% during the second quarter, HoldingsChannel.com reports. The fund owned 469,765 shares of the biotechnology companys stock after selling 1,030,235 shares during the quarter. Point72 Asset Management L.P.s holdings in Aeglea BioTherapeutics were worth $3,270,000 at the end of the []
   Aeglea BioTherapeutics EPS misses by $0.01  2021/11/04 11:58:38 Seeking Alpha
   Aeglea BioTherapeutics Reports Third Quarter 2021 Financial Results and Corporate Highlights  2021/11/04 11:01:00 PR Newswire
AUSTIN, Texas, Nov. 4, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced financial results for the third…
   Aeglea BioTherapeutics Announces Presentation of Seven Abstracts at ICIEM 2021 Including Oral Presentation of PEACE Study Baseline Characteristics  2021/11/04 10:59:00 Business Insider Markets
AUSTIN, Texas, Nov. 4, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced that
   Aeglea BioTherapeutics (AGLE) Investor Presentation - Slideshow  2021/09/10 18:05:21 Seeking Alpha
   Aeglea Biotherapeutics Inc (AGLE) CFO Jonathan Alspaugh Bought $262,822 of Shares  2021/08/19 18:15:05 GuruFocus
Related Stocks: AGLE ,
   Aeglea BioTherapeutics reports Q2 results  2021/08/05 13:13:43 Seeking Alpha
   Were Hedge Funds Right About Aeglea BioTherapeutics, Inc. (AGLE)?  2021/07/26 15:50:08 Insider Monkey
   Aeglea Biotherapeutics names Jonathan Alspaugh as chief financial officer  2021/07/08 12:37:01 Seeking Alpha

calendar